Literature DB >> 7907940

Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.

T Nakamura1, H Nekarda, A H Hoelscher, E Bollschweiler, N Harbeck, K Becker, J R Siewert, N ] Harbec N [corrected to Harbeck.   

Abstract

BACKGROUND: During the last two decades, a rising incidence of adenocarcinoma of the esophagus has been observed in the Western world. The prognostic relevance of tumor-biological factors, such as DNA ploidy or c-erbB-2 overexpression, for overall survival following complete resection is still unknown.
METHODS: In a retrospective study of 80 patients with adenocarcinoma of Barrett's esophagus, the prognostic significance of flow cytometric DNA ploidy determination was investigated. Overexpression of c-erbB-2 oncoprotein was studied by immunohistochemical alkaline phosphatase-antialkaline phosphatase staining of formalin fixed, paraffin embedded tissue sections of the primary tumor.
RESULTS: The rate of aneuploidy was 86%. Aneuploidy was significantly correlated with lymph node metastases only. c-erbB-2 oncoprotein overexpression of the primary tumor was detected in 15 patients (19%). A significant correlation was seen between c-erbB-2 overexpression and depth of tumor invasion, lymph node involvement, distant metastases, and status of residual tumor after resection (R category, International Union Against Cancer [UICC], 1987). All primary tumors with c-erbB-2 oncoprotein overexpression were aneuploid. In a multivariate Cox regression analysis for overall survival of those 62 patients (78%) whose tumor resection was macroscopically and microscopically complete (R0-UICC), depth of invasion, distant metastases, and c-erbB-2 overexpression were independent prognostic factors. The relative risk of death due to recurrence was nearly identical for patients with either c-erbB-2 oncoprotein overexpression or distant metastases: 4.06 (1.4-11.8) and 3.94 (1.6-9.5). In a multivariate Cox regression analysis of the subgroup of lymph node-negative patients (n = 26), the ploidy status of the primary tumor (defined as near-diploid plus tetraploid versus aneuploid plus multiploid) was the only independent prognostic factor for overall survival.
CONCLUSIONS: These findings demonstrate that DNA ploidy as well as c-erbB-2 oncoprotein overexpression are valuable prognostic factors in patients with adenocarcinoma of Barrett's esophagus after complete tumor resection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7907940     DOI: 10.1002/1097-0142(19940401)73:7<1785::aid-cncr2820730703>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  Gallbladder cancer. A comparative study among clinicopathologic features, AgNORs, and DNA content analysis.

Authors:  J E Nishizawa-Takano; H Ayabe; K Hatano; H Yamaguchi; Y Tagawa
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

3.  Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.

Authors:  R Langer; B H A Von Rahden; J Nahrig; C Von Weyhern; R Reiter; M Feith; H J Stein; J R Siewert; H Höfler; M Sarbia
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

4.  Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma.

Authors:  Yong Chen; Shuang-Mei Zhu; Xiao-Ling Xu; A N Zhao; Jin-Lin Hu
Journal:  Oncol Lett       Date:  2015-11-25       Impact factor: 2.967

Review 5.  Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.

Authors:  David S Y Chan; Christopher P Twine; Wyn G Lewis
Journal:  J Gastrointest Surg       Date:  2012-07-28       Impact factor: 3.452

Review 6.  Staging of squamous esophageal cancer: accuracy and value.

Authors:  A H Hölscher; H J Dittler; J R Siewert
Journal:  World J Surg       Date:  1994 May-Jun       Impact factor: 3.352

7.  The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas.

Authors:  W Vogel; R Kath; H Kosmehl; E Olschowsky; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.

Authors:  Ashwini Gowryshankar; Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

9.  Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.

Authors:  Ellie Chan; Lizette Vila Duckworth; Ahmad Alkhasawneh; Tania Zuluaga Toro; Xiaomin Lu; Kfir Ben-David; Steven J Hughes; Georgios Rossidis; Robert Zlotecki; Judith Lightsey; Karen C Daily; Long Dang; Carmen J Allegra; Brent King; Thomas J George
Journal:  J Gastrointest Oncol       Date:  2016-04

10.  Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.

Authors:  Tadayuki Akagi; Tetsuo Ito; Motohiro Kato; Zhe Jin; Yulan Cheng; Takatsugu Kan; Go Yamamoto; Alexandru Olaru; Norihiko Kawamata; Jessica Boult; Harmik J Soukiasian; Carl W Miller; Seishi Ogawa; Stephen J Meltzer; H Phillip Koeffler
Journal:  Int J Cancer       Date:  2009-11-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.